Factors associated with success of telaprevir- and boceprevir-based triple therapy for hepatitis C virus infection

AIM: To evaluate new therapies for hepatitis C virus (HCV), data about real-world outcomes are needed. METHODS: Outcomes of 223 patients with genotype 1 HCV who started telaprevir- or boceprevir-based triple therapy (May 2011-March 2012) at the Mount Sinai Medical Center were analyzed. Human immunod...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:World J Hepatol
Hlavní autoři: Bichoupan, Kian, Tandon, Neeta, Martel-Laferriere, Valerie, Patel, Neal M, Sachs, David, Ng, Michel, Schonfeld, Emily A, Pappas, Alexis, Crismale, James, Stivala, Alicia, Khaitova, Viktoriya, Gardenier, Donald, Linderman, Michael, Olson, William, Perumalswami, Ponni V, Schiano, Thomas D, Odin, Joseph A, Liu, Lawrence U, Dieterich, Douglas T, Branch, Andrea D
Médium: Artigo
Jazyk:Inglês
Vydáno: Baishideng Publishing Group Inc 2017
Témata:
Observational Study
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5395804/
https://ncbi.nlm.nih.gov/pubmed/28469811
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4254/wjh.v9.i11.551
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky